Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash from Financing Activities (2020 - 2025)

Barinthus Biotherapeutics' Cash from Financing Activities history spans 6 years, with the latest figure at $2000.0 for Q1 2025.

  • For Q1 2025, Cash from Financing Activities fell 99.6% year-over-year to $2000.0; the TTM value through Dec 2025 reached $2000.0, down 99.91%, while the annual FY2025 figure was $2000.0, 99.91% down from the prior year.
  • Cash from Financing Activities reached $2000.0 in Q1 2025 per BRNS's latest filing, down from $837000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $121.8 million in Q1 2021 to a low of -$1.4 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $15.1 million, with a median of $358000.0 recorded in 2024.
  • The largest YoY upside for Cash from Financing Activities was 5277.78% in 2022 against a maximum downside of 100.13% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $9000.0 in 2021, then surged by 5277.78% to $484000.0 in 2022, then tumbled by 77.48% to $109000.0 in 2023, then skyrocketed by 667.89% to $837000.0 in 2024, then crashed by 99.76% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Cash from Financing Activities are $2000.0 (Q1 2025), $837000.0 (Q4 2024), and $465000.0 (Q3 2024).